Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Chardan Capital Markets Starts Assembly Biosciences (ASMB) at Buy, "Sensitivity analyses suggest considerable upside"
-
Spring Bank Pharmaceuticals (SBPH) PT More than Doubled to $34 at Chardan Capital Markets
-
Castlight Health to Participate in Upcoming Investor Conferences
-
Chardan Capital Markets Starts Model N, Inc. (MODN) at Buy; Undervalued Versus Peers
-
Smith Micro (SMSI) Announces $2.2M Registered Direct Offering of Common Stock
-
Smith Micro Announces $2.2 Million Registered Direct Offering of Common Stock
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $110 at Chardan Capital Markets
-
Chardan Capital Markets Downgrades CaesarStone Sdot-Yam (CSTE) to Neutral on Valuation
-
Astrotech (ASTC) Subsidiary to Pursue Strategic Alternatives
-
Astrotech Subsidiary 1st Detect to Pursue Strategic Alternatives
-
Alnylam Pharmaceuticals (ALNY) PT Trimmed to $95 at Chardan Capital Markets
-
Lion Biotechnologies (LBIO) PT Raised to $20 at Chardan Capital Markets, "Leader In Precision Immuno-Oncology"
-
Chardan Capital Markets Starts Spring Bank Pharmaceuticals (SBPH) at Buy; Can Lead in HBV
-
Forum Merger Corporation Class A Common Stock, Warrants and Rights to Commence Trading Separately on May 2, 2017
-
REGENXBIO Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
-
Chardan Capital Markets Reiterates Sell Rating and $6.50 PT on Akari Therapeutcis (AKTX); 'Weak Efficacy for Coversin in the Ph2 PNH COBALT Trial'
-
SRAX Announces Offering of $3.72 Million of Secured Convertible Debentures
-
Akari Therapeutics (AKTX) PT Raised to $6.50 at Chardan Capital Markets; 'Skepticism on Coversin in PNH'
-
Forum Merger Corporation Completes $150,000,000 Initial Public Offering
-
PlacementTracker Publishes Q1 2017 Private Placement Market League Tables
-
Lion Biotechnologies (LBIO): Reiterating Buy - Chardan
-
Regenxbio Inc. (RGNX) PT Raised to $50 at Chardan Capital Markets on News Dr. Olivier Danos is New CSO; 'Watershed Moment'
-
Ohr Pharmaceutical Announces Closing of Public Offering of Common Stock and Warrants
-
Forum Merger Corporation Announces Pricing of $150 Million Initial Public Offering
-
Ohr Pharmaceutical (OHRP) Prices $14.175M Offering of Common Stock and Warrants
-
Ohr Pharmaceutical Announces Pricing of $14.175 Million Public Offering of Common Stock and Warrants
-
Ohr Pharmaceutical (OHRP) Reports Proposed Equity Offering
-
Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants
-
Pre-Open Movers 04/04: (GNCMA) (PRTK) (CYCC) Higher; (AYI) (KATE) (NVDA) Lower (more...)
-
Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Buy
-
WPCS Closes $968,000 Financing
-
Ritter Pharma (RTTR): Cutting PT After Phase II Data Fails To Meet Endpoint - Chardan
-
Pre-Open Movers 03/28: (PSIX) (CARA) (SB) Higher; (CYRX) (ORIG) (MEET) Lower (more...)
-
Biocept (BIOC) to Sell 4.32M Shares at $2.15 with Warrants
-
Biocept Announces Pricing of $9.3 Million Financing
-
After-Hours Stock Movers 03/27: (PSIX) (OCN) (RHT) Higher; (CYRX) (EVH) (STOR) Lower (more...)
-
Chardan Capital Markets Starts CRISPR Therapeutics (CRSP) at Buy
-
Chardan Capital Markets Starts Editas Medicine (EDIT) at Buy
-
Chardan Capital Markets Starts Intellia Therapeutics (NTLA) at Buy
-
Teladoc (TDOC): Management Confident on NDR - Chardan
-
La Jolla Pharmaceutical (LJPC) Prices 3.7M Common Stock Offering at $33.50/Share
-
La Jolla Pharmaceutical Company Announces Pricing of Public Offering of Common Stock
-
HealthEquity, Inc (HQY) PT Raised to $53 at Chardan Capital Markets Following Q4 Beat and Positive Guidance
-
Regenxbio (RGNX) Reports Pricing of 3.7M Share Offering at $20.50
-
REGENXBIO Announces Pricing of Public Offering of Common Stock
-
Regenxbio (RGNX) Plans $75M Common Stock Offering
-
REGENXBIO Announces Proposed Public Offering of Common Stock
-
Chardan Capital Markets Reiterates Buy on Benefitfocus (BNFT) Following Analyst Day
-
Chardan Capital Markets Reiterates Buy on Cogent (COGT) Following 4Q
-
Profire Energy (PFIE) PT Raised to $2.15 at Chardan Capital Markets; Estimates Raised

